ArticleThe Journal of infection2024
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines.
Abstract readLetter
In one paragraph
Article in The Journal of infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.Scientific reports · 2026Article
- First exposure to SARS-CoV-2 shapes IgG subclass switching after mRNA vaccination.Communications medicine · 2026Article
- Simultaneous quantification of anti-Spike IgG subclasses against various SARS-CoV-2 variants using a multiplex serological assay.Medical microbiology and immunology · 2026Article
- Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2.Scientific reports · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273.Infectious diseases and therapy · 2026Article
- Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections.Human vaccines & immunotherapeutics · 2025Article
- Article
- Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant.Science advances · 2025Article
- Article
- Cohort-resolved excess mortality in Germany (2000-2024): Patterns and implications for the SARS-CoV-2 era.PloS one · 2025Article
- T and B cell responses in different immunization scenarios for COVID-19: a narrative review.Frontiers in immunology · 2025Review
- Post-COVID syndrome patients show reduced anti-Spike antibodies compared to COVID-recovered controls, but enhanced IgG4/IgG1 switch after the third vaccine dose.Frontiers in immunology · 2025Article
- Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.Influenza and other respiratory viruses · 2025Review
- Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults.Immunity & ageing : I & A · 2024Article
- An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines.Scientific reports · 2024Article
- Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding.NPJ vaccines · 2024Article
- Evaluation of antibody responses in healthy individuals receiving SARS-CoV-2 inactivated vaccines.Biosafety and health · 2024Article
Corrections and comments
- Update of
Authors and funding
15 authors.
Raj KalkeriNovavax, Inc., Gaithersburg, MD, USA. Electronic address: RKalkeri@novavax.com.
Mingzhu ZhuNovavax, Inc., Gaithersburg, MD, USA.
Shane Cloney-ClarkNovavax, Inc., Gaithersburg, MD, USA.
Joyce S PlestedNovavax, Inc., Gaithersburg, MD, USA.
Anand ParekhNovavax, Inc., Gaithersburg, MD, USA.
Drew GorinsonNovavax, Inc., Gaithersburg, MD, USA.
Rongman CaiNovavax, Inc., Gaithersburg, MD, USA.
Soham MahatoNovavax, Inc., Gaithersburg, MD, USA.
Pradhipa RamanathanDepartment of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Lidwina Carissa AureliaDepartment of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Kevin John SelvaDepartment of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Anthony M MarcheseNovavax, Inc., Gaithersburg, MD, USA.
Louis FriesNovavax, Inc., Gaithersburg, MD, USA.
Amy W ChungDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Lisa M DunkleNovavax, Inc., Gaithersburg, MD, USA.
Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MNIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI68614NIAID NIH HHS UM1 AI68635NIAID NIH HHS UM1 AI68636
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibody FormationCOVID-19Antibodies, ViralCOVID-19 VaccinesHumansSARS-CoV-2Antibodies, ViralCOVID-19 Vaccines
Identifiers
PMID
38360356What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.